The global atypical hemolytic uremic syndrome (aHUS) treatment market is on a growth trajectory, expected to attain a value of US$ 2,308.84 million by 2033, expanding at a CAGR of 4.9% from 2023 to 2033. Currently valued at US$ 1,431 million in 2023, the market has experienced steady growth, recording a CAGR of 3.4% between …